Overview
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
Status:
Completed
Completed
Trial end date:
2007-03-01
2007-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasisPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Alza Corporation, DE, USA
Criteria
Inclusion Criteria:- Diagnosis of plaque psoriasis for at least 6 months
- willingness to undergo tissue biopsies
Exclusion Criteria:
- No current oral or injectable medications for psoriasis (30 days to 3 months)
- no other major health issues